Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Bavarian Nordic A/S ADR

Healthcare US BVNRY

8.97USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

9.279.55
LowHigh

52 Week Range

7.7513.00
LowHigh

Fundamentals

  • Previous Close 8.97
  • Market Cap2323.94M
  • Volume500
  • P/E Ratio10.90
  • Dividend Yield-%
  • EBITDA1653.59M
  • Revenue TTM6243.96M
  • Revenue Per Share TTM26.65
  • Gross Profit TTM 3071.77M
  • Diluted EPS TTM0.92

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1731.79M 971.36M 1482.94M -331.61100M -454.43000M
Minority interest - - - - -
Net income 1322.56M 987.98M 1475.19M -347.38200M -464.77500M
Selling general administrative 671.21M 516.14M 540.85M 376.02M 292.92M
Selling and marketing expenses - 500.34M 331.58M 212.93M 191.78M
Gross profit 2812.33M 2818.76M 4526.77M 1701.26M 570.32M
Reconciled depreciation 714.37M 624.90M 1111.50M 399.25M 388.31M
Ebit 885.42M 1049.23M 1497.97M -3.84500M -263.31400M
Ebitda 1572.36M 1674.13M 2051.79M 395.40M 125.00M
Depreciation and amortization 686.94M 624.90M 553.82M 399.25M 388.31M
Non operating income net other - - - - -
Operating income 885.42M 939.77M 1497.52M -3.84500M -263.31400M
Other operating expenses 5048.62M 4776.44M 5559.80M 3221.58M 2211.42M
Interest expense 12.63M 77.87M 105.52M 119.69M 152.06M
Tax provision 425.58M -16.62000M 7.75M 15.77M 10.35M
Interest income 36.87M 48.31M 40.21M 0.03M 1.74M
Net interest income 2.28M -45.27200M -63.01500M -65.27300M -118.13600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 409.23M -16.62000M 7.75M 15.77M 10.35M
Total revenue 5934.04M 5716.21M 7062.34M 3150.79M 1897.88M
Total operating expenses 1926.91M 1878.99M 3024.23M 1772.05M 883.86M
Cost of revenue 3121.72M 2897.45M 2535.57M 1449.53M 1327.56M
Total other income expense net 846.37M 31.59M -14.58000M -327.76600M -191.11600M
Discontinued operations - - - - -
Net income from continuing ops 1375.38M 987.98M 1475.19M -347.38200M -464.77500M
Net income applicable to common shares - - - -347.38200M -464.77500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14953.24M 14405.86M 14353.21M 12391.25M 12089.27M
Intangible assets 5959.13M 6330.89M 6481.74M 5942.64M 5803.96M
Earning assets - - - - -
Other current assets 34.25M 104.86M 113.73M 720.34M 556.98M
Total liab 2084.28M 2997.30M 4013.28M 5241.26M 4714.60M
Total stockholder equity 12868.96M 11408.56M 10339.93M 7149.99M 7374.67M
Deferred long term liab - - - - -
Other current liab 574.26M 1710.33M 1779.98M 551.34M 23.92M
Common stock 792.30M 788.55M 780.98M 707.35M 704.68M
Capital stock 792.37M 788.55M 780.98M 707.35M 704.68M
Retained earnings 11816.37M 10434.20M 9330.00M 6300.57M 6588.91M
Other liab - - - 2891.08M 2729.60M
Good will - - - - -
Other assets 0.00001M - - 212.62M 43.16M
Cash 1714.35M 1623.49M 1477.23M 575.41M 591.82M
Cash and equivalents - - - - -
Total current liabilities 1597.39M 2797.01M 2787.87M 2287.34M 1908.56M
Current deferred revenue 9.95M - 7.21M - 725.39M
Net debt -1583.49105M -1495.24000M -1331.93200M 1183.92M 540.77M
Short term debt 45.51M 41.54M 46.55M 1130.07M 895.64M
Short long term debt 2.15M 2.07M 1.91M 1105.58M 874.37M
Short long term debt total 130.86M 128.25M 145.30M 1759.33M 1132.59M
Other stockholder equity -9.66816M 185.82M 228.95M 142.06M 81.08M
Property plant equipment - - - 1751.41M 1488.51M
Total current assets 6736.73M 5787.00M 5403.05M 4484.58M 4753.64M
Long term investments - - - - -
Net tangible assets - - - 1207.35M 1570.71M
Short term investments 1618.86M 551.54M 390.25M 2269.76M 3124.80M
Net receivables 855.56M 1179.80M 1778.10M 523.14M 447.95M
Long term debt 10.89M 13.05M 15.13M 583.43M 179.41M
Inventory 2513.70M 2327.31M 1643.74M 919.07M 480.04M
Accounts payable 967.66M 1045.13M 954.14M 605.93M 263.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 269.96M 188.66M 230.49M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 73.26M 45.51M 15.74M 212.62M 43.16M
Deferred long term asset charges - - - - -
Non current assets total 8216.52M 8618.87M 8950.16M 7906.67M 7335.63M
Capital lease obligations 117.83M 113.12M 128.25M 70.32M 78.81M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1125.57200M -1870.86300M -945.56400M -877.40500M -1779.45400M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -2389.44209M -1870.86300M -945.56400M -877.40500M -2876.94600M
Net borrowings -2.09000M -1.92100M -865.54500M 607.34M 638.32M
Total cash from financing activities -109.96637M 55.77M 735.83M 635.82M 3536.08M
Change to operating activities - - - 423.41M -146.00700M
Net income 1322.56M 987.98M 1475.19M -347.38200M -464.77500M
Change in cash 280.80M 146.26M 901.83M -16.41300M 306.33M
Begin period cash flow 1433.55M 1477.23M 575.41M 591.82M 285.49M
End period cash flow 1714.35M 1623.49M 1477.23M 575.41M 591.82M
Total cash from operating activities 2617.38M 1949.83M 1119.21M 220.05M -358.50000M
Issuance of capital stock 78.67M 126.79M 1687.43M 37.92M 2963.78M
Depreciation 686.94M 624.90M 553.82M 399.25M 388.31M
Other cashflows from investing activities - -1604.97600M -834.88000M -169.46000M -39.04100M
Dividends paid - - - - -
Change to inventory -179.44372M -683.57300M -599.01500M -439.02900M 41.04M
Change to account receivables 100.66M 617.86M -1345.42700M -133.16700M -364.39300M
Sale purchase of stock -144.35599M -27.45900M -8.98800M -9.32800M -8.58100M
Other cashflows from financing activities -39.16542M -41.63900M -77.06500M 981.57M 583.05M
Change to netincome - - - 318.15M 193.20M
Capital expenditures 197.40M 1687.64M 977.40M 1381.58M 1058.45M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 132.24M 176.91M -1550.95900M -148.78900M -469.36100M
Stock based compensation 84.49M 78.67M 55.48M 49.28M 56.86M
Other non cash items 177.29M 81.37M 585.68M 267.69M 140.88M
Free cash flow 2419.97M 262.19M 141.80M -1161.52200M -1416.95100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BVNRY
Bavarian Nordic A/S ADR		 - -% 8.97 10.90 4.97 0.37 1.18 1.91 4.73
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S ADR

Philip Heymans Alle 3, Hellerup, Denmark, 2900

Key Executives

Name Title Year Born
Dr. Paul John Chaplin MSc, Ph.D. CEO & Pres 1967
Mr. Henrik Juuel M.Sc. CFO & Exec. VP 1965
Mr. Russell Thirsk Exec. VP & COO NA
Mr. Rolf Sass Sørensen VP of Investor Relations & Communications NA
Ms. Anu Helena Kerns Exec. VP & Chief People Officer 1972
Mr. Jean-Christophe May Exec. VP & Chief Commercial Officer 1967
Dr. Laurence De Moerlooze Exec. VP & Chief Medical Officer 1964
Dr. Paul John Chaplin MSc, Ph.D. CEO & President 1967
Mr. Henrik Juuel M.Sc. CFO & Executive VP 1965
Mr. Russell Thirsk M.Sc. Executive VP & COO 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions